To obtain a new compound useful for bone diseases such as osteoporosis and chronic arthrorheumatism, capable of suppressing bone absorption by osteoclast.
This new compound is shown by the formula A-B-D-E-F-G {A is a group of formula I (Y is an NR2, O, etc.; R2 is H, a 1-10C alkyl, etc.; (q) is 0 or 1; a group of formula II is a five- to tenmembered cyclic base; B is a direct bond, a 1-8C alkanediyl, etc.; D and F are each a direct bond, a 1-8C alkanediyl, etc.; E is a template selected from fibrinogen receptor antagonists; G is a group of formula III [R4 to R7 are each H, F, OH, etc.; R10 is C(O)R11 (R11 is OH, a 1-8C alkoxy, etc.), C(S)R11, etc.]} such as a human vitronectin receptor. The compound of the formula is obtained by condensing a compound of the formula A-B-D-E-M (M is hydroxycarbonyl, etc.) with a compound of the formula HNR2k-G. For example, in the case of A-B is a ground of formula IV, a compound of formula V is reacted with a sulfonic acid of the formula Q-S(O)n-D-E-F-G or its derivative to give the objective compound.
STILZ HANS-ULRICH DR
PEYMAN ANUSCHIRWAN DR
SCHEUNEMANN KARLHEINZ DR
RUXER JEAN-MARIE DR
CARNIATO DENIS DR
LEFRANCOIS JEAN-MICHEL
GADEK THOMAS RICHARD DR
MCDOWELL ROBERT DR
GENENTECH INC
Next Patent: NITROGEN MONOXIDE SYNTHETASE INHIBITOR